JP7332469B2 - スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物 - Google Patents

スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物 Download PDF

Info

Publication number
JP7332469B2
JP7332469B2 JP2019519978A JP2019519978A JP7332469B2 JP 7332469 B2 JP7332469 B2 JP 7332469B2 JP 2019519978 A JP2019519978 A JP 2019519978A JP 2019519978 A JP2019519978 A JP 2019519978A JP 7332469 B2 JP7332469 B2 JP 7332469B2
Authority
JP
Japan
Prior art keywords
compound
cancer
compounds
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019519978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532067A5 (enExample
JP2019532067A (ja
Inventor
オロンスキー，ブライアン，ティー．
サイシンスキー，ジャン
Original Assignee
エピセントアールエックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピセントアールエックス，インコーポレイテッド filed Critical エピセントアールエックス，インコーポレイテッド
Publication of JP2019532067A publication Critical patent/JP2019532067A/ja
Publication of JP2019532067A5 publication Critical patent/JP2019532067A5/ja
Application granted granted Critical
Publication of JP7332469B2 publication Critical patent/JP7332469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019519978A 2016-10-14 2017-10-13 スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物 Active JP7332469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408182P 2016-10-14 2016-10-14
US62/408,182 2016-10-14
PCT/US2017/056454 WO2018071741A1 (en) 2016-10-14 2017-10-13 Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine

Publications (3)

Publication Number Publication Date
JP2019532067A JP2019532067A (ja) 2019-11-07
JP2019532067A5 JP2019532067A5 (enExample) 2020-11-26
JP7332469B2 true JP7332469B2 (ja) 2023-08-23

Family

ID=61906413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019519978A Active JP7332469B2 (ja) 2016-10-14 2017-10-13 スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物

Country Status (13)

Country Link
US (1) US11008287B2 (enExample)
EP (1) EP3526195A4 (enExample)
JP (1) JP7332469B2 (enExample)
KR (1) KR20190128619A (enExample)
CN (1) CN110352190A (enExample)
AU (2) AU2017342436C1 (enExample)
BR (1) BR112019007453A2 (enExample)
CA (1) CA3040479A1 (enExample)
EA (1) EA201990949A1 (enExample)
IL (1) IL265970B (enExample)
MX (1) MX2019004280A (enExample)
SG (1) SG11201903312VA (enExample)
WO (1) WO2018071741A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
CN118236371A (zh) 2016-01-11 2024-06-25 埃皮辛特瑞柯斯公司 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
EP3526195A4 (en) 2016-10-14 2020-05-20 EpicentRx, Inc. SULFOXYALKYLE ORGANONITRO, RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE
IL271777B2 (en) 2017-07-07 2024-09-01 Epicentrx Inc Compositions for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
AU2022294071A1 (en) * 2021-06-16 2024-01-04 Epicentrx, Inc. Organonitro and sulfoxyalkyl organonitro compounds for use in treating medical disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506974A (ja) 1996-10-11 2001-05-29 ワーナー―ランバート・コンパニー インターロイキン―１β変換酵素のアスパルテートエステル阻害剤
WO2006102760A1 (en) 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
JP2014530811A (ja) 2011-10-07 2014-11-20 レイディオアーレックス・インコーポレイテッドＲａｄｉｏＲｘ，Ｉｎｃ． 有機ニトロチオエーテル化合物およびその医療用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2978453A (en) 1956-12-12 1961-04-04 Aerojet General Co 3, 3, 5, 5-tetranitropiperidine
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5511509A (en) 1978-07-07 1980-01-26 Toomasu Gorudon Robaato Cancer therapy
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
GB8728418D0 (en) 1987-12-04 1988-01-13 Jenkins T C Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5693794A (en) 1988-09-30 1997-12-02 The United States Of America As Represented By The Secretary Of The Navy Caged polynitramine compound
JP2659614B2 (ja) 1990-11-13 1997-09-30 株式会社日立製作所 表示制御装置
TW198712B (enExample) * 1991-04-17 1993-01-21 Hoffmann La Roche
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0611306B1 (en) 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
US5336784A (en) 1993-06-07 1994-08-09 The Regents Of The University Of California Synthesis of 1,3,3-trinitroazetidine
WO1995032715A1 (en) 1994-05-27 1995-12-07 Neptune Pharmaceutical Corporation Nitric oxide donor composition and method for treatment of anal disorders
WO1996028205A1 (en) 1995-03-14 1996-09-19 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
ES2140069T3 (es) 1995-03-14 2000-02-16 Siemens Ag Dispositivo atomizador ultrasonico con unidad dosificadora de precision desmontable.
US5580988A (en) 1995-05-15 1996-12-03 The United States Of America As Represented By The Secretary Of The Army Substituted azetidines and processes of using them
WO1996036602A1 (en) 1995-05-15 1996-11-21 The United States Of America Adnaz, compositions and processes
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
AU3129097A (en) 1996-10-15 1998-05-11 Eastman Chemical Company Explosive formulations
GB9720797D0 (en) 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6056966A (en) 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
WO2000006143A1 (en) 1998-07-27 2000-02-10 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6391911B1 (en) 1999-02-26 2002-05-21 Robert E. Bases Coadministration of lucanthone and radiation for treatment of cancer
US20020077276A1 (en) 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
CZ20023213A3 (cs) 2000-04-10 2003-12-17 Pfizer Products Inc. Benzoamidové piperidinové sloučeniny a příbuzné sloučeniny
US6861530B2 (en) 2000-07-07 2005-03-01 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
DE10111049A1 (de) 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2003247792B2 (en) 2002-07-03 2009-09-24 Nicox S.A. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
AU2003282534A1 (en) 2002-10-07 2004-05-04 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
WO2004098538A2 (en) 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
CA2531543C (en) 2003-06-25 2010-10-12 Je Il Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
AU2004255268B2 (en) 2003-07-09 2010-04-01 Loma Linda University Use of nitrite salts for the treatment of cardiovascular conditions
GB0326047D0 (en) 2003-11-07 2003-12-10 Univ Sheffield Substance
WO2006029385A2 (en) 2004-09-08 2006-03-16 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
JP2009510073A (ja) 2005-09-27 2009-03-12 ノバルティス アクチエンゲゼルシャフト カルボキシアミン化合物およびその使用方法
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US8122281B2 (en) 2007-04-13 2012-02-21 International Business Machines Corporation System and method for dependent failure-aware allocation of distributed data-processing systems
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
US20120149678A1 (en) 2010-12-09 2012-06-14 Oronsky Bryan T Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto
US8664247B2 (en) * 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
CN118236371A (zh) 2016-01-11 2024-06-25 埃皮辛特瑞柯斯公司 2-溴-1-(3，3-二硝基氮杂环丁烷-1-基)乙酮静脉施用的组合物和方法
EP3526195A4 (en) 2016-10-14 2020-05-20 EpicentRx, Inc. SULFOXYALKYLE ORGANONITRO, RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE
IL271777B2 (en) 2017-07-07 2024-09-01 Epicentrx Inc Compositions for parenteral administration of therapeutic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506974A (ja) 1996-10-11 2001-05-29 ワーナー―ランバート・コンパニー インターロイキン―１β変換酵素のアスパルテートエステル阻害剤
WO2006102760A1 (en) 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
JP2014530811A (ja) 2011-10-07 2014-11-20 レイディオアーレックス・インコーポレイテッドＲａｄｉｏＲｘ，Ｉｎｃ． 有機ニトロチオエーテル化合物およびその医療用途

Also Published As

Publication number Publication date
CA3040479A1 (en) 2018-04-19
EA201990949A1 (ru) 2019-10-31
MX2019004280A (es) 2019-09-18
IL265970B (en) 2022-03-01
CN110352190A (zh) 2019-10-18
KR20190128619A (ko) 2019-11-18
AU2017342436A1 (en) 2019-05-02
SG11201903312VA (en) 2019-05-30
AU2022203169A1 (en) 2022-06-02
EP3526195A4 (en) 2020-05-20
AU2022203169B2 (en) 2024-04-18
US11008287B2 (en) 2021-05-18
IL265970A (en) 2019-06-30
AU2017342436B2 (en) 2022-05-19
US20200157047A1 (en) 2020-05-21
WO2018071741A1 (en) 2018-04-19
AU2017342436C1 (en) 2022-11-03
EP3526195A1 (en) 2019-08-21
WO2018071741A8 (en) 2019-05-31
BR112019007453A2 (pt) 2019-07-16
JP2019532067A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
JP7332469B2 (ja) スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物
JP6019126B2 (ja) 有機ニトロチオエーテル化合物およびその医療用途
CN101583606B (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
KR101454936B1 (ko) Ｂｃｌ 단백질과 결합 파트너의 상호작용을 억제하기 위한 화합물 및 방법
JP6440690B2 (ja) シクロアルキル酸誘導体、その製造方法、およびその医薬適用
AU2015274781C1 (en) Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
JP2019533659A (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換ヘテロ環
KR20070006891A (ko) 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
JP2010521527A5 (enExample)
WO2023016529A1 (zh) 作为atr抑制剂的萘啶衍生物及其制备方法
US20190040040A1 (en) Pyridazine derivatives as eaat2 activators
US20220241425A1 (en) Small molecule target bromo/acetyl proteins and uses thereof
CN116490201A (zh) Yap/taz-tead肿瘤蛋白的抑制剂，其合成和用途
JP2006515334A (ja) ＣＲＦ受容体アンタゴニストとしてのヘテロアリール置換ピロロ［２，３−ｂ］ピリジン誘導体
JP2008520644A (ja) オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
AU2017290897B2 (en) Deuterated compounds for treating pain
CN119278034A (zh) 选择性组蛋白去乙酰化酶8(hdac8)降解剂和其使用方法
US20240002378A1 (en) Merged scaffold taf1 inhibitors
CN118647617A (zh) 稠杂环类化合物、其制备方法及其在医药上的应用
HK40106135A (zh) 作为ulk1/2抑制剂的2，4-二氨基嘧啶衍生物及其用途
WO2024109917A1 (zh) 一种三唑衍生物及其在医药上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230810

R150 Certificate of patent or registration of utility model

Ref document number: 7332469

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150